This Clinical Trial Is Making HIV Treatment Easier for Black People
Parenting/ HealthLifestyle / Parenting/ Health 2 weeks ago 39 Views 0 comments
Black Americans are disproportionately affected by HIV/AIDS in the United States, facing a staggering 42 percent of new HIV infections despite only making up 13 percent of the population. This disparity translates to poorer health outcomes, with Black Americans experiencing a nine-fold higher death rate from HIV/AIDS compared to white counterparts. These grim statistics highlight the urgent need for improved HIV treatment strategies specifically tailored to the Black community.
The BRAAVE2020 Study for HIV
A new study published in the Journal of Acquired Immune Deficiency Syndromes (JAIDS) offers a beacon of hope. The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a single-pill regimen called Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF). This treatment approach has become a preferred option for many due to its convenience and effectiveness. However, prior clinical trials often lacked sufficient Black participation, raising concerns about whether B/F/TAF would be equally beneficial for this population.
The BRAAVE2020 study addressed this knowledge gap by specifically recruiting Black adults with HIV. Nearly 500 participants with well-controlled viral suppression on existing medications were enrolled. Half the group switched to B/F/TAF, while the rest continued their current regimens. The results were clear: after 24 weeks, both groups achieved similar...
0 Comments